Anti-cd38 antibodies for the treatment of acute myeloid leukemia

CN107406506BActive Publication Date: 2026-05-29JANSSEN BIOTECH INC
View PDF 45 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
JANSSEN BIOTECH INC
Filing Date
2015-12-02
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Current treatments for acute myeloid leukemia (AML) are ineffective, with a 5-year relapse-free survival rate of less than 30%, necessitating more effective treatments.

Method used

Anti-CD38 antibodies are used to competitively bind to CD38 against antibodies containing specific heavy chain variable regions (VH) and light chain variable regions (VL) for the treatment of AML.

Benefits of technology

It significantly reduces leukemia cells in bone marrow, spleen, and peripheral blood, downregulates CD38 expression, enhances treatment efficacy, and improves the survival rate of AML patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN107406506B_ABST
    Figure CN107406506B_ABST
Patent Text Reader

Abstract

The present invention relates to methods of treating acute myeloid leukemia with anti-CD38 antibodies.
Need to check novelty before this filing date? Find Prior Art